#United States #Newark #Conformal Medical #CLAAS AcuFORM #W. L. Gore

W. L. Gore & Associates Expands into Innovative Endovascular Solutions

In a strategic move set to transform the landscape of endovascular treatments, W. L. Gore & Associates, Inc. has announced its acquisition of Conformal Medical, Inc. This new partnership aims to incorporate the groundbreaking CLAAS® AcuFORM™ system into Gore’s already robust medical solutions portfolio. The deal is expected to finalize in early 2026, pending regulatory approval, and signifies a major leap forward in elevating patient care through advanced technology.

The Future of Cardiac Treatment

The CLAAS AcuFORM system represents a next-generation approach to left atrial appendage closure, a crucial procedure for patients suffering from non-valvular atrial fibrillation (AFib). This innovative system features a unique scaffold made from nitinol and a proprietary foam matrix, designed to conform to a variety of anatomical structures with just a few sizes. By potentially transforming the left atrial appendage closure into an outpatient procedure, it aims to significantly reduce the need for general anesthesia and overnight hospital stays.

Bret Snyder, the chairman and CEO of Gore, expressed his confidence in the acquisition, highlighting, "The CLAAS AcuFORM experimental system embodies the type of transformative and scientific innovation that aligns with our long-term commitment to enhancing patient care." This acquisition not only complements Gore’s existing product range but also reinforces their position at the forefront of medical device innovation.

Tackling Atrial Fibrillation

According to the American Heart Association, the prevalence of AFib is projected to exceed 12 million cases in the United States by 2030, making it crucial to develop efficient treatment options to mitigate risks associated with this condition. The left atrial appendage closure procedure helps prevent blood clots, which can lead to strokes, allowing some patients to forgo long-term oral anticoagulation therapy.

The partnership between Gore and Conformal is a powerful alliance that combines Conformal’s specialized expertise in left atrial appendage closure with Gore’s world-class technological development and operational capabilities. James Reinstein, CEO of Conformal Medical, commented, “We are thrilled to partner with Gore, sharing a common belief that the CLAAS AcuFORM device can be transformative for stroke prevention.” Reinstein emphasized that the collaboration would leverage Gore’s global presence to expedite bringing this novel solution to patients worldwide.

A Legacy of Innovation

With a history spanning over five decades, W. L. Gore has been at the forefront of medical technology innovation, introducing numerous devices that address cardiovascular disorders and other health challenges. The company’s legacy includes more than 50 million medical devices implanted globally, all aimed at improving patient outcomes through diligent research and quality initiatives.

As part of its continuous focus on innovation, Gore has recognized the potential of the CLAAS AcuFORM system to change the paradigm of outpatient procedures in cardiology. With the merger, both companies anticipate a significant reduction in healthcare costs through improved device performance and ease of use, benefiting medical professionals, hospitals, and insurers alike.

Looking Ahead

Gore aims to further its mission of enhancing lives through strategic partnerships and innovative medical solutions. The acquisition of Conformal Medical is a testament to this mission, signifying a commitment not only to technological advancement but also to patient-centered care.

In conjunction with this acquisition, BDT MSD Partners acted as financial advisor and Davis Polk served as legal advisor for W. L. Gore. Meanwhile, Piper Sandler provided financial advisory services and Gunderson Dettmer acted as Conformal’s legal counsel.

As W. L. Gore continues pushing boundaries in medical technology, the global health community eagerly awaits the potential benefits these new innovations may bring to patient care.